Readily Diagnostics

1. 27 Aug 2026

   Grant

   €811K

   Cumulative €811K

Amounts in EUR, converted at the ECB rate on the event date. Funding totals exclude debt, grants and state aid; rounds whose instrument is not yet established are still counted. Every figure links to its source.

• Funding27 Aug 2026EUR 811K

  Readily Diagnostics has raised approximately €811k from the Gates Foundation to develop an affordable test for common sexually transmitted infections.

  ▸Source: EU-Startups

  “Readily Diagnostics, a Swedish point-of-care diagnostics company, has received a grant of approximately €811k (about 9 million SEK) from the Gates Foundation to develop an affordable test for the…”

  Read at EU-Startups

• Liza Löf

  CEO

What does Readily Diagnostics do?

Readily Diagnostics is a Swedish point-of-care diagnostics company that develops sensitive, specific and rapid diagnostic testing for infectious disease. The project targets three infections: chlamydia, gonorrhea and trichomoniasis. Readily is developing a point-of-care platform that delivers a molecular diagnostic result close to the patient, with no need for central laboratories. The company explains that in many low- and middle-income countries, people are treated on symptoms alone, because accurate testing is too slow, too costly, or unavailable.

Where is Readily Diagnostics headquartered?

Readily Diagnostics is based in Sweden.

How much funding has Readily Diagnostics raised?

Readily Diagnostics has raised €811K (across 1 round · last 27 Aug 2026).

What was Readily Diagnostics's latest funding round?

Readily Diagnostics's most recent disclosed round was a grant round of €811K, announced 27 August 2026.

Who has invested in Readily Diagnostics?

Investors in Readily Diagnostics include Gates Foundation.